Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report
/in Dendritic Cells, International Publications, NSCLC /von 2024-02-10 / J Med Case Rep 2024 Feb;18(1):88Radioimmunotherapy With WT1 Dendritic Cell Vaccine for End-Stage Lung Adenocarcinoma Markedly Shrinks Tumors
/in Dendritic Cells, International Publications, NSCLC /von 2023-11-06 / Cureus 2023 Nov;15(11):e48412The DC-T cell axis is an effective target for the treatment of non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2023-11-01 / Immun Inflamm Dis 2023 Nov;11(11):e1099WT1 Dendritic Cell Vaccine Therapy Improves Immune Profile and Prolongs Progression-Free Survival in End-Stage Lung Cancer
/in Dendritic Cells, International Publications, NSCLC /von 2023-10-19 / Cureus 2023 Oct;15(10):e47320Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment
/in Dendritic Cells, International Publications, NSCLC /von 2023-10-04 / Cells 2023 Oct;12(19)Tumor cell vaccine combined with Newcastle disease virus promote immunotherapy of lung cancer
/in International Publications, Newcastle Disease Virus, NSCLC /von 2023-02-01 / J Med Virol 2023 Feb;95(2):e28554A Single-Arm Phase II Study to Evaluate Efficacy and Safety of First-Line Treatment With DCVAC/LuCa, Standard of Care Chemotherapy and Shenqi Fuzheng Injection in Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer Patients
/in Dendritic Cells, International Publications, NSCLC /von 2022-01-01 / Integr Cancer Ther 2022;21:15347354221083968Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers
/in Dendritic Cells, International Publications, NSCLC /von 2021-12-24 / ESMO Open 2022 Feb;7(1):100334Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2021-11-24 / World J Clin Oncol 2021 Nov;12(11):966-982
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Interview mit Prof. Dr. Volker Schirrmacher im Klassik Radio
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum